After administering an OV, PD-L1 expression is up-regulated on the surface of immune cells and tumor cells to evade T cell attack in vivo, which is responsible for tumor resistance and immune escape to OV-based immunotherapy. This evidence concerns the gene CD274 and neoplasm.